Skip to main content

Table 3 Treatment regimens for CD and UC patients

From: Drug utilization and cost associated with inflammatory bowel disease management in Saudi Arabia

 CD (N = 258)UC (N = 249)P-valueAntibioticsCorticosteroids
Prescribed medicationsa, n (%)
 None8 (3.10)17 (6.83)0.04*1 (0.20)2 (0.39)
 AZA + INFX69 (26.74)9 (3.61)< 0.01*7 (1.38)4 (0.79)
 AZA64 (24.81)6 (2.41)< 0.01*2 (0.39)4 (0.79)
 AZA + ADA23 (8.91)2 (0.80)< 0.01*1 (0.20)0
 ADA22 (8.53)3 (1.20)< 0.01*1 (0.20)1 (0.20)
 INFX18 (6.20)0< 0.01*1 (0.20)2 (0.40)
 AZA + mesalazine14 (5.43)55 (22.09)< 0.01*2 (0.39)2 (0.39)
 Mesalazine9 (3.49)113 (45.38)< 0.01*07 (1.38)
 AZA + mesalazine + INFX4 (1.55)11 (4.42)0.0700
 AZA + mesalazine + ADA3 (1.16)15 (6.02)< 0.0101 (0.20)
 AZA + SSZ2 (0.78)00.5000
 Mesalazine + INFX3 (1.16)7 (2.81)0.171 (0.20)2 (0.39)
 Mesalazine + SSZ + UST1 (0.39)0101(0.20)
 Mesalazine + MTX + AZA1 (0.39)0100
 ADA + mesalazine2 (0.78)3 (1.20)101 (0.20)
 Mesalazine + AZA + SSZ01 (0.40)0.4900
 AZA + SSZ + INF01 (0.40)0.4900
 Certolizumab + MTX1 (0.39)0101 (0.20)
 ADA + Mesalazine + 6MP01 (0.40)0.4900
 AZA + certolizumab2 (0.78)00.5000
 ADA + MTX2 (0.78)00.5000
 AZA + vedolizumab1 (0.39)0101 (0.20)
 Certolizumab3 (1.16)00.2500
 Ustekinumab2 (0.78)0101 (0.20)
 AZA + MTX + ADA1 (0.39)0100
 AZA + UST1 (0.39)0100
 Vedolizumab + MTX1 (0.39)011 (0.20)1 (0.20)
 AZA + mesalazine + golimumab01 (0.40)0.4900
 6MP + mesalazine + vedolizumab01 (0.40)0.491 (0.20)1 (0.20)
 INFX + MTX1 (0.39)0100
 SSZ01 (0.40)0.4900
 Vedolizumab01 (0.40)0.4900
 Golimumab0000
 6MP01 (0.40)0.4900
  1. *Indicates statistically significant difference
  2. aAZA azathioprine, INFX infliximab, ADA adalimumab, SSZ sulfasalazine, UST ustekinumab, MTX methotrexate, 6MP 6-mercaptopurine